THE COST-EFFECTIVENESS OF OCTREOTIDE ACETATE IN THE TREATMENT OF CARCINOID-SYNDROME AND VIPOMA

Authors
SCHONFELD WH ELKIN EP WOLTERING EA MODLIN IM ANTHONY L VILLA KF ZAGARI M
Citation
Wh. Schonfeld et al., THE COST-EFFECTIVENESS OF OCTREOTIDE ACETATE IN THE TREATMENT OF CARCINOID-SYNDROME AND VIPOMA, International journal of technology assessment in health care, 14(3), 1998, pp. 514-525
Citations number
19
Categorie Soggetti
Public, Environmental & Occupation Heath","Medical Informatics","Health Care Sciences & Services
Journal title
International journal of technology assessment in health care → ACNP
ISSN journal
02664623
Volume
14
Issue
3
Year of publication
1998
Pages
514 - 525
Database
ISI
SICI code
0266-4623(1998)14:3<514:TCOOAI>2.0.ZU;2-X
Abstract
Markov modeling was used to evaluate the cost-effectiveness of octreot ide in treating carcinoid syndrome and VIPoma. For each condition, usi ng octreotide was associated with doubled survival time. Octreotide wa s cost-effective for treating carcinoid tumor ($752 per additional yea r of life, two additional years on average), and cost saving for VIPom a.